Fagron NV operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Fagron NV with three other
pharmaceutical manufacturers in Europe:
Dechra Pharmaceuticals PLC
of UNITED KINGDOM
sales of £481.80 million [US$628.16 million]
of which 63%
was European Pharmaceuticals),
(557.12 million Euros [US$660.88 million]
of which 53%
was OTC Specialities and Other Products), and
based in GERMANY
(446.44 million Euros [US$529.58 million]
of which 76%
was EVT Execute).
During the year ended December of 2019, sales at
Fagron NV were 534.70 million Euro (US$634.28 million).
increase of 13.4%
versus 2018, when the company's sales were 471.68 million Euro.
This was the third consecutive year of growth at Fagron NV.
Sales of Fagron North America saw an increase
that was more than double the company's growth rate: sales were up
28.6% in 2019, from
113.49 million Euro to 145.91 million Euro.
Fagron NV also saw significant increases in sales in
Fagron South America (up 24.4% to 125.55 million Euro)
Not all segments of Fagron NV experienced an increase in sales in 2019:
sales of Hl Technology fell 13.1% to 6.23 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).